/PRNewswire/ iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival.
FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (£59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
/PRNewswire/ iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival.